Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood

Information

  • Patent Grant
  • 10688239
  • Patent Number
    10,688,239
  • Date Filed
    Monday, January 14, 2019
    5 years ago
  • Date Issued
    Tuesday, June 23, 2020
    4 years ago
Abstract
The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.
Description
FIELD OF THE INVENTION

The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood; use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood; use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein; and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.


BACKGROUND

Biology


During a long evolution, many pathogenic microorganisms have learned to exploit eukaryotic cell surface glycoconjugates, i.e. glycolipids, glycoproteins and proteoglycans, as receptor molecules for cell attachment to facilitate tissue colonization and invasion processes. In brief, specific proteins called adhesins of the surface of bacteria, viruses, fungi and parasites interact with carbohydrate chains of glycoconjugates which enable microbes to colonize mucosal surfaces and tissue lesions.


The role of sialic acid in binding of pathogens to host cells has been reported over many years. Only recently proteoglycans with their carbohydrate chains (glycosaminoglycans) were shown to bind many different pathogens. By removing terminal carbohydrate moieties of these various glycoconjugates with sialidase and other exoglycosidases or with glycosaminoglycan (GAG) degrading enzymes on the cells in monolayers, these structures were proven to be receptor molecules for various sialoadhesins and heparan sulfate binding proteins (HeBPs).


These mechanisms are summarized in a review article by Siiri Hirmo, Meeme Utt and Torkel Wadström, Biology, Biochemistry, Clinical Biochemistry, Volume 12, including Proceedings from the 17th International Lectin Meeting in Würzburg, 1997, edited by Edilbert van Driessche, Sonia Beeckmans and Thorkild C. Bog-Hansen, published by TEXTOP, Lemchesvej 11, DK-2900 Hellerup, Denmark, ISBN number 87-984583-0-2.


During microbial infections, inflammatory mediators are released and activated. These so-called “pro-inflammatory cytokines” include tumor necrosis factor alpha and beta (TNF-α and TNF-β), interleukin-1 (IL-1), and interleukin-6 (IL-6). These cytokines are part of the inflammatory response of sepsis. Multiple organ failure induced by sepsis is currently the leading cause of death in intensive care units.


In connection with microbial infections and cardiovascular surgery, for instance cardiopulmonary bypass, inflammatory responses are elicited and have a multitude of biological consequences, ranging from subclinical organ dysfunction to severe multiorgan failure. Cytokines are thought to be important mediators in this response.


The cytokines mentioned above have a capacity to bind selectively to a range of glycosaminoglycans, or GAGs, including heparan sulfate in tissues and on the surface of both endothelial cells and leucocytes.


Receptors


Heparan sulfate is a glycosaminoglycan that is present on the surface of almost all mammalian cells. It is built up by alternating D-glucosamine and uronic acid residues (L-iduronic and D-glucuronic). Heparan sulfates are highly charged (sulfated) heterogeneous polysaccharides and represent the carbohydrate portion of many glycoconjugates (syndecan, perlecan, glypican) on the cell surface.


Many microbes utilize heparan sulfates on the surface of the mammalian cell as receptors. This mechanism is general and valid for almost all bacteria, virus and parasites. Some microorganisms utilize more than one glycoconjugate receptor. Examples of other receptors that are used together with heparan sulfate are specific chondroitin sulfates and sialic acid containing glycoproteins.


Heparan sulfate/chondroitin sulfate binding microbes are exemplified by viruses like herpes simplex virus type 1 (HSV-1), causative agent of orolabial herpes; herpes simplex virus type 2 (HSV-2), causative agent of genital herpes; cytomegalovirus (CMV), the major complicating agent in immunosuppressed patients; dengue virus, which causes recurrent fevers; and human immunodeficiency virus (HIV); and by bacteria like Helicobacter pylori, Streptococcus sanguis, Streptococcus mutans, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Mycobacterium tuberculosis; and parasites like Plasmodium falciparum (which causes malaria), and Trypanosoma cruzi (which causes trypanosomiasis).


Further, cytokines, like TNF-β, also utilize heparan sulfate on cell surfaces for binding and activation.


Heparin as a Receptor


Heparin is a polysaccharide, which is isolated from mammalian tissue. Since its discovery in 1916 by the American scientist McLean, heparin has been recognized for its blood anticoagulant properties and heparin has, for more than 50 years, been used clinically as a blood anticoagulant and antithrombotic agent.


Whereas heparan sulfates are ubiquitous components of all tissue-organized animal life forms, heparin has a very particular distribution in mammalian tissue. Heparin is, in contrast to the heparan sulfates, present only in the basophilic granules of mast cells. However, today, in addition to its established place in prevention and therapy of thromboembolic disorders, heparin has demonstrated a broad spectrum of different activities independent of anticoagulation.


A large number of proteins in blood bind, with high affinity, to heparin and/or heparan sulfate. Examples are antithrombin (AT), fibronectin, vitronectin, growth factors (e.g. the fibroblast growth factors, the insulin like growth factors etc). Human serum albumin (HSA) also binds, but with a lower affinity. On the other hand, HSA is present in large amounts in blood.


To utilize these properties of heparin for hindering infections, introducing heparin fragments and/or sialic containing fragments into the vascular system has been contemplated. Thereby, it was thought, these fragments would bind to the lectins on the microbes, block them and thus hinder them from binding to the receptors on the mammalian cell surface. This concept has been tried by many scientists but with limited success, in most cases due to bleeding complications when large amounts of heparin are introduced into the vascular system.


U.S. Pat. No. 6,197,568 dicloses methods for isolation and detection of flaviviruses and other hemorrhagic fever viruses, such as dengue virus, based on the sulfated polyanion-dependent interaction of flaviviruses and hemorrhagic fever viruses.


Extracorporeal devices are used in a variety of clinical situations including kidney dialysis, cardiopulmonary bypass and plasmapheresis.


“Extracorporeal therapies” means procedures in which desired products like oxygen, blood-anticoagulants, anesthetics etc can be added to body fluids. Conversely, undesired products like toxins etc can be removed from body fluids outside the body. Examples are haemodialysis and haemofiltration which represent technologies whereby blood is rinsed from waste products.


SUMMARY OF THE INVENTION

An object of the present invention is to provide a method for treatment of a mammal suffering from diseases or conditions caused or aggravated by different pathogenic microbes, inflammatory cells or inflammatory proteins by removal of said pathogenic microbes, inflammatory cells or inflammatory proteins from the blood of said mammal.


Another object of the present invention is to provide a method for extracorporeal removal of pathogenic microbes, inflammatory cells or inflammatory proteins from mammalian blood.


The above mentioned objects, as well as further objects of the invention, which should be apparent to a person skilled in the art after having studied the description below, are accomplished by the different aspects of the present invention as described herein.


A first aspect of the present invention provides a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood, comprising the steps:

    • a) providing a sample of mammalian blood,
    • b) bringing said sample into contact with a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, inflammatory cell or inflammatory protein, under conditions allowing binding of any pathogenic microbes, inflammatory cells and inflammatory proteins in said blood sample to the carbohydrate,
    • c) separating the sample from the solid substrate, such that said pathogenic microbe, inflammatory cell or inflammatory protein is at least partially retained on the solid substrate, and
    • d) recovering said sample containing a reduced amount of said pathogenic microbe, inflammatory cell or inflammatory protein.


The prior-art concept of introducing heparin fragments and/or sialic containing fragments into the vascular system of patients has shown limited success, in most cases due to bleeding complications when large amounts of heparin are introduced into the vascular system. The method according to the invention circumvents these problems by the carbohydrates being immobilized on a solid surface, as is inter alia described in Preparatory example 6.


Use of immobilized carbohydrates as defined by the method according to the invention also provides a further unexpected advantage. The inventors have found that the carbohydrate has to be immobilized onto a solid surface to have the capacity that is necessary for binding a significant amount of the compounds that are to be removed. This unexpected property is described in Comparative example 1 and Example 1 for HSV-1, showing that in solution, less than 3% of the virus binds to an excess of heparin (Comparative example 1) while more than 94% of the virus binds to immobilized heparin (Example 1).


The method of the present invention enables safe and efficient treatment of patients suffering from sepsis or septic shock by removing pathogens causative of the condition from the patient's blood stream. The method of the present invention allows removal of many different pathogenic microbes, inflammatory cells and inflammatory proteins. Examples of pathogenic microbes commonly associated with sepsis that may be removed using the method of the invention include staphylococci, such as Staphylococcus aureus, streptococci and E. coli.


As both heparin and heparan sulfates bind to a large number of components, as exemplified in the background section, it was expected that a heparin surface would be covered with many of these proteins, when brought into contact with blood, thus preventing the microbes from attaching. The present inventors have surprisingly found that highly efficient purification of serum and whole blood from mammals, including humans, can be achieved using a method and a device according to the present invention. It is disclosed herein that a column of moderate size managed to almost completely remove considerable amounts of viruses from blood serum and whole blood. See e.g. Examples 2, 3 and 4.


In an embodiment, said pathogenic microbe is selected from the group consisting of bacteria, viruses and parasites.


In an embodiment, said pathogenic microbe is a virus. In a more specific embodiment, said virus is selected from the group consisting of herpes simplex virus type 1, herpes simplex virus type 2, Influenza A virus, cytomegalovirus and human immunodeficiency virus. In another more specific embodiment, said virus is selected from the group consisting of herpes simplex virus type 1 or herpes simplex virus type 2.


In another embodiment, said pathogenic microbe is a bacterium. In a more specific embodiment, said bacterium is selected from the group consisting of Helicobacter pylori, Streptococcus sanguis, Streptococcus mutans, Staphylococcus aureus, Escherichia coli, Pseudomonas aureginosa and Mycobacterium tuberculosis. In a preferred embodiment, said pathogenic microbe is Helicobacter pylori or Staphylococcus aureus.


In yet another embodiment, said pathogenic microbe is a parasite. In a more specific embodiment, said parasite is selected from the group consisting of Plasmodium falciparum and Trypanosoma cruzi.


In a further embodiment, said inflammatory cell is selected from the group consisting of inflammatory lymphocytes and inflammatory macrophages.


In yet a further embodiment, said inflammatory protein is a pro-inflammatory cytokine. In a more specific embodiment, said pro-inflammatory cytokine is selected from the group consisting of tumor necrosis factor alpha (TNF-α), tumor necrosis factor beta (TNF-β), interleukin-1 (IL-1), and interleukin-6 (IL-6).


In an embodiment, said mammalian blood is human blood.


In an embodiment of the inventive method, said carbohydrate is selected from the group consisting of heparin, heparan sulfate, chondroitin sulfate, carbohydrates comprising sialic acid and carbohydrates comprising neuramic acid. In a more specific embodiment, said carbohydrate is heparin.


In yet another embodiment, said solid substrate comprises microparticles or hollow fibres. In certain embodiments of the invention, the material of said solid substrate is selected from the group consisting of glass, cellulose, cellulose acetate, chitin, chitosan, crosslinked dextran, crosslinked agarose, polypropylene, polyethylene, polysulfone, polyacrylonitrile, silicone, Teflon and polyurethanes.


In a further embodiment, said carbohydrate is covalently linked to said solid substrate. In a more specific embodiment, said carbohydrate is linked to said solid substrate by covalent end-point attachment. Covalent attachment of a carbohydrate to a solid substrate provides better control of parameters such as surface density and orientation of the immobilized molecules as compared to non-covalent attachment. These parameters have been shown by the inventors to be important in order to provide optimal pathogen binding to the immobilized carbohydrate molecules. The surface concentration of the carbohydrate on the solid substrate should preferably be in the range of 1-10 μg/cm2. Covalent end-point attachment means that the carbohydrate is covalently attached to the solid substrate via the terminal residue of the carbohydrate molecule. A second aspect of the present invention provides use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of a pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood.


Embodiments of a use according to the second aspect of the invention correspond to those specified above for the method according to the first aspect of the present invention regarding the pathogenic microbe, inflammatory cell, inflammatory protein, mammalian blood, carbohydrate, solid substrate and immobilization.


A third aspect of the invention provides use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by a pathogenic microbe, inflammatory cell or inflammatory protein.


Embodiments of a use according to the third aspect of the invention correspond to those specified above for the method according to the first aspect of the present invention regarding the pathogenic microbe, inflammatory cell, inflammatory protein, mammalian blood, carbohydrate, solid substrate and immobilization.


A device as referred to in the use and method according to the invention may comprise a conventional device for extracorporeal treatment of blood and serum from patients, e.g. suffering from renal failure.


Local blood flow patterns in blood contacting medical devices for extracorporeal circulation are known to influence clot formation via shear activation and aggregation of platelets in stagnant zones. Consequently, a device as used in the second, third and fourth aspects of the invention should be designed in a fashion that does not create these problems.


A device as used in some embodiments of the invention may for example have the following properties:

    • A blood flow in the range of 1-500 ml/min, preferably 5-250 ml/min.
    • Low flow resistance.
    • Large surface area of substrate having carbohydrates immobilized thereto, e.g. about 0.1-1 m2.
    • Stable coating (no leakage of carbohydrate to the blood in contact therewith).
    • Proper haemodynamic properties in the device (no stagnant zones).
    • Optimal biocompatibility.


A non-limiting example of such a device, which can be used in a use or a method according to the present invention, is a pediatric haemoflow dialyzer such as the Prisma M10 haemofilter/dialyzer from Gambro AB, Sweden. Other models or types of devices for extracorporeal treatment of blood or serum may also be used.


A fourth aspect of the present invention provides a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein, comprising the steps:

    • a) extracting blood from the subject,
    • b) bringing the extracted blood into contact with a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, under conditions allowing binding of a pathogenic microbe, an inflammatory cell or an inflammatory protein to the carbohydrate, and
    • c) reintroducing the blood, containing a reduced amount of said pathogenic microbe, inflammatory cell or inflammatory protein, into the blood-stream of the subject.


In an embodiment of the treatment method according to the present invention, the extraction and reintroduction of blood is performed in a continuous loop, which loop comprises a part of the bloodstream of the subject.


Embodiments of a method for treatment according to the fourth aspect of the invention correspond to those specified above for the method according to the first aspect of the present invention regarding the pathogenic microbe, inflammatory cell, inflammatory protein, mammalian blood, carbohydrate, solid substrate and immobilization.


As used herein, the term “pathogenic microbe” means a microbe, which can cause disease in a living organism when introduced into said organism. Examples of “pathogenic microbes” include bacteria, viruses and parasites.


As used herein, the term “inflammatory cell” means a cell, which is involved in inflammatory response in a mammal. Examples of “inflammatory cells” include inflammatory lymphocytes and inflammatory macrophages.


As used herein, the term “inflammatory protein” means a protein, such as a cytokine, released for instance in connection with microbial infection or immunization.


As used herein, the term “cytokine” means a protein, released for instance in connection with microbial infection or immunization, selected from the group consisting of interleukins, interferons, chemokines and tumour necrosis factors.







EXAMPLES
Preparatory Example 1

Amination of Sephadex G 25


Sodium metaperiodate (NaIO4, 6.0 g) was dissolved in water (994 ml) and added to Sephadex G 25 (Pharmacia Biotech, Uppsala, Sweden) (50 g) in 1 l water. The mixture was kept in the dark under shaking for 24 h. After filtration and washing with water 5×1 l and finally 0.1 M phosphate buffer, pH 7.0, the resulting product was suspended in phosphate buffer, pH 7.0 (350 ml) and a solution of polyethylenimine (100 ml Lupasol (BASF, Germany), 5% in water) was added. The gel was stabilized by addition of an aqueous solution of NaBH3CN, sodium cyanoborohydride (0.5 g in 100 ml, phosphate buffer, 0.1 M, pH 7.0). The gel was filtered and washed as described above and finally washed with acetate buffer (500 ml, 0.1 M, pH 4.0), yielding aminated Sephadex G 25 (85 g).


Preparatory Example 2

Covalent End-Point Attachment of Heparin onto a Chromatographic Gel


Aminated Sephadex G 25 (85 g) obtained as described in Preparatory example 1 was suspended in acetate buffer (800 ml, 0.1 M, pH 4.0) and 4.0 g nitrous acid degraded heparin (heparin from Pharmacia, Sweden) was added. After shaking for 0.5 h, NaBH3CN (0.4 g) was added. The reaction mixture was shaken for 24 h and then processed as above, yielding heparinized Sephadex G 25 (80 g).


The gel contains 2% heparin (w/w, sulfur analysis). The Sephadex G 25 beads have an average diameter of 50-150 μm. A rough calculation reveals that 1 cm3 contains 106 beads which gives a bead surface area of 0.03 m2/cm3. Further, if heparin is attached only to the surface of the beads, a heparinized Sephadex G 25 with 2% heparin w/w has about 0.003 μg heparin/cm2.


Preparatory Example 3

Covalent Attachment of Heparin onto Aminated Glass Wool


A glass wool material is heparinized using the general procedure described below.


Glass wool is thoroughly cleaned with acid (HCl), rinsed with absolute ethanol, and dried in an oven at 100° C. for 4 hours.


Reactive amino functions are introduced on the glass wool surface by treatment with an aqueous solution of polyamine, polyethylenimine (PEI) or chitosan. For some purposes, the polyamines may be stabilized on the surface by crosslinking with bifunctional reagents, such as crotonaldehyde or glutaraldehyde.


The coating is further stabilized by ionic cross linking with a sulfated polysaccharide (dextran sulfate or heparin). If necessary, these steps are repeated and a sandwich structure is built up. Careful rinsing (water, suitable buffers) should be performed between each step. After a last addition of PEI or chitosan, end-point attachment (EPA) to the aminated surface of native heparin is done by reductive amination, utilizing the aldehyde function in the reducing terminal residue in native heparin. The coupling is performed in aqueous solution, by reductive amination (cyanoborohydride, CNBH3) essentially as described in Preparatory example 2.


Surface analysis as described in Preparatory example 2 reveals that approximately 10 mg/cm2 of heparin is coupled to the glass surface.


Preparatory Example 4

Covalent Attachment of Heparin onto Aminated Polymeric Surfaces


A polymeric surface was heparinized using the general procedure described below.


The polymeric surface is etched with a oxidizing agent (potassium permanganate, ammoniumperoxidisulfate) in order to introduce hydrophilic characteristics together with some reactive functional groups (—SO3H, —OH, —C═O, —C═C—). The surface can also be etched with plasma or corona.


Reactive amino functions are introduced by treatment with a polyamine, polyethylenimine (PET) or chitosan. For some purposes the polyamines may be stabilized on the surface by cross linking with bifunctional reagents, such as crotonaldehyde or glutaraldehyde.


The coating is further stabilized by ionic cross linking with a sulfated polysaccharide (dextran sulfate or heparin). If necessary these steps are repeated and a sandwich structure is built up. Careful rinsing (water, suitable buffers) should be performed between each step. After a last addition of PEI or chitosan, end-point attachment (EPA) to the aminated surface of native heparin is done by reductive amination, utilizing the aldehyde function in the reducing terminal residue in native heparin. A more reactive aldehyde function in the reducing terminal residue can be achieved by partial, nitrous degradation of heparin. This shortens the reaction time, but the immobilized heparin will have a lower molecular weight. The coupling is performed in aqueous solution, by reductive amination (cyanoborohydride, CNBH3) essentially as described in Preparatory example 2.


1-10 μg/cm2 of heparin can be coupled to all hydrophilic surfaces like glass, cellulose, chitin etc, and more or less all hydrophobic polymers like polyvinyl chloride, polyethylene, polycarbonate, polystyrene, PTFE etc.


Preparatory Example 5

Covalent Single- or Multipoint Attachment of Heparin onto Polymeric Surfaces


Performed as described in Preparatory example 2, with the exception that the aldehyde functions were introduced in the heparin chain by oxidation with sodium periodate in aqueous solution.


Preparatory Example 6

Attachment of Heparin onto the Inner Lumen of Hollow Fibers


In this preparatory example, a pediatric haemoflow dialyzer was used. The fibers of the dialyzer were made of polysulfone with an inner diameter of 200 microns and a wall thickness of 40 microns. The total surface area of the blood contacting material was 4000 cm2 and the priming volume was 28 ml.


The amination procedure was performed as generally described in Preparatory example 4 with the exception that the etching step was omitted. Polysulfone is hydrophilic and does not need etching. Immobilization of heparin was performed by pumping a solution containing nitrous acid degraded heparin (heparin from Pharmacia) together with NaBH3CN as described in Preparatory example 2. As measurement of the amount of heparin is a destructive procedure, a reference dialyzer that was heparinized under identical conditions was sacrificed and its fibers are subjected to sulfur analysis. The results revealed a heparin content of about 5 μg heparin/cm2, which corresponds to a content of 20 mg heparin in the device.


Preparatory Example 7

Covalent Attachment of Oligomers with Terminal Sialic Acid Residues onto the Inner Lumen of Hollow Fibers


In this preparatory example, the aldehyde group at the reducing terminal residue was used for coupling. Amination of the fibers was performed as described in Preparatory example 6 and coupling of the oligosaccharide of formula 1, which contains terminal sialic acid residues, was performed by circulating the compound of formula 1, dissolved in acetate buffer (800 ml, 0.1 M, pH 4.0) together with NaBH3CN (0.4 g), at room temperature for 24 h. The results revealed a sialic acid content of ca. 2 μg/cm2.




embedded image


Comparative Example 1

Binding of HSV-1 to Heparin in Solution


A solution (10 μl) containing 107 plaque forming units of virus (Herpes simplex virus type 1 strain KOS321) was incubated with 20 μl of 3H-labelled heparan sulfate (HS) in a total volume of 400 μl of buffered NaCl for 30 min at 37° C. Thereafter, the solution was centrifuged through a Microsep 1 M filter, retaining virus and bound HS. 2.3% of HS was bound (479 CPM) to the virus, while 97.7% of the HS was unbound and passed through the filter.


Example 1

Removal of HSV-1 and HSV-2 Virus Particles from Buffered Saline by Binding to Heparin Immobilized on Sephadex Beads


Sephadex beads coated with heparin, as in Preparatory example 2, were soaked in buffered NaCl (PBS) and 0.8 ml was transferred to each of two small disposable columns, forming a gel layer of approximately 1 cm. After washing three times, 50 μl of 3H-thymidine radiolabelled viruses were suspended in 150 μl of PBS. 109 plaque forming units of HSV-1, corresponding to 1011 virus particles, were added to column 1, and 108 plaque forming units of HSV-2, corresponding to 1010 virus particles, were added to column 2. Virus was allowed to adsorb to the respective columns. Thereafter, 0.8 ml of PBS was added to each column and the pass-through fluid was collected for estimation of unabsorbed virus.


Subsequently, both columns were washed 4 times with 1 ml of PBS, and the washings were collected as fractions for quantification of washed out virus. These, and the following fractions, were transferred to scintillation vials and quantified with regard to amount of virus through determination of cpm in a beta counter. In the next step, the columns were subjected to elution of the respective heparin-bound viruses three times by 1 ml of 2 M NaCl, and the three fractions were collected from each column. Following that, elution was performed by twice adding 1 ml of 5% SDS in PBS (PBS-SDS), and the two fractions from each column were collected. Finally, the heparin-coated beads from the two columns were each suspended in 1 ml of PBS-SDS, and 200 μl aliquots were subjected to quantification of remaining bound virus particles by determination of radioactivity.


The results are shown in Table 1 below. As shown, only 5.5% of HSV-1 particles and 11.7% of HSV-2 particles did not adsorb to the column. Moreover, since the viral DNA and not their heparin-binding proteins are labeled with radioactivity, these non-adsorbed particles might represent non-infectious viruses with disrupted envelopes (i.e. the outer, fragile, parts of the virus that bind to heparin). The rest of the viruses (94.5% for HSV-1 and 88.3% of HSV-2) bind to the heparin-coated beads in the column. The binding appears to be strong, judging from the fact that only 0.5% of HSV-1 and 1.1% of HSV-2 was removed by 4 successive washings. The limited ability of 2 M NaCl at 3 successive attempts to elute the viruses underscores the high-affinity characteristic of the binding of both viruses to the heparin-coated beads. In contrast, substantial quantities of HSV-1 and HSV-2 were eluted by PBS-SDS.


A total of 48% of HSV-1 and 68.8% of HSV-2 were recovered from the columns. This can be attributed to the fact that 2 M NaCl spontaneously decreased the radioactivity of the samples by approximately 30% according to our past observations, and that SDS-PBS probably also has this effect.


Taken together, the results prove the principle that HSV-1 and HSV-2 virus particles can be removed from a fluid phase by passage through a short column containing heparin-coated Sephadex beads, and that extracted viruses bind with high affinity to the columns.









TABLE 1







Binding of radiolabelled HSV virus particles, suspended


in buffered NaCl, to heparin-Sephadex beads.


Binding of HSV to heparin column (% of input virus = control = 100%)










HSV-1
HSV-2














Input virus (control)
100.0
100.0



Unadsorbed virus
5.5
11.7



Washed from column





1st washing
0.2
0.4



2nd washing
0.1
0.3



3rd washing
0.1
0.2



4th washing
0.1
0.2



total unadsorbed + washed
6.0
12.8



Eluted with 2M NaCl





1st elution
7.8
14.7



2nd elution
1.6
1.9



3rd elution
0.1
1.3



Eluted with 5% SDS





1st elution
10.6
11.9



2nd elution
18.5
18.3



total eluted NaCl + SDS
38.6
48.1



Uneluted from beads
4.1
7.9



total uneluted
4.1
7.9



Total recovered
48.7
68.8



(unadsorbed + washed +





eluted + uneluted)









Example 2

Removal of HSV-1 Virus Particles from Human Serum by Binding to Heparin Immobilized on Sephadex Beads


The experimental procedure as described in Example 1 was utilized with the difference that the radiolabelled HSV-1 virus particles at a quantity of 109 PFU equivalent to 1011 virus particles were mixed with 0.5 ml of human serum and then applied on heparin-coated beads in a disposable column. Thereafter, the procedure including elution and washing was followed as in Example 1. The results are shown in Table 2 below.









TABLE 2





Binding of radiolabelled HSV-1 virus particles (1011),


suspended in human serum, to heparin-Sephadex beads (1 cm3).


Binding of HSV-1 to heparin column (% of input virus = control = 100%)


















Input virus (control)
100.0



Unabsorbed virus
2.4



Washed from column




1st washing
0.9



2nd washing
0.2



3rd washing
0.1



4th washing
0.2



total unabsorbed + washed
3.8



Eluted with 2M NaCl




1st elution
2.1



2nd elution
0.4



3rd elution
0.2



Eluted with 5% SDS




1st elution
3.5



total eluted NaCl + SDS
6.2



Total recovered
10.0



(unabsorbed + washed +




eluted + uneluted)




Remained on beads
90.0









As shown, 97.6% of the HSV-1 particles suspended in human serum were bound to the column. By washing 4 times, only 3.8 of the virus particles were removed. Using 2 M NaCl, only 2.7% of the virus was eluted, and an additional 3.5% were eluted by SDS. The conclusion of these results is that suspending virus in serum, which is the real life situation during severe, disseminated infection, improved the performance of the virus-removing column as regards binding of radiolabelled virus, and that only 2.4% of the HSV-1 particles were unadsorbed. As a probable explanation, serum proteins helped to stabilize the virus particles and thereby improved the removal of HSV-1 by the heparinized Sephadex beads.


Example 3

Removal of HSV-1 Virus Particles from Human Serum by Binding to Heparin Immobilized on a Hollow Fiber Haemoflow Dialyzer


The experimental procedure as described in Example 1 was utilized with the difference that the radiolabelled HSV-1 virus particles at a quantity of 109 PFU equivalent to 1011 virus particles were mixed with 0.5 ml of human serum and then applied on the heparin-coated hollow fiber dialyzer of Preparatory example 6. Thereafter, the procedure including elution and washing was followed as in Example 1. The results are shown in Table 3 below.


As shown, 92.3% of the HSV-1 particles suspended in human serum were bound to the column. By washing 4 times, only 4.2% of the virus particles were removed. By 2 M NaCl, only 4.0% of the virus was eluted, and an additional 4.5% were eluted by SDS. The conclusion of these results is that the binding of virus particles suspended in human serum to heparinized fibers is comparable to that of similarly suspended virus binding to heparin-coated Sephadex beads, and that only 7.7% of the HSV-1 particles were unabsorbed.









TABLE 3





Binding of radiolabelled HSV-1 virus particles,


suspended in human serum, to heparinized hollow fibers.


Binding of HSV-1 to heparin column (% of input virus = control = 100%)


















Input virus (control)
100.0



Unabsorbed virus
7.7



Washed from column




1st washing
3.1



2nd washing
0.8



3rd washing
0.1



4th washing
0.2



total unadsorbed + washed
4.2



Eluted with 2M NaCl




1st elution
3.3



2nd elution
0.5



3rd elution
0.2



Eluted with 5% SDS




1st elution
4.5



total eluted NaCl + SDS
8.5



Total recovered
12.7



(unabsorbed + washed +




eluted + uneluted)




Remained on beads
87.3









Example 4

Removal of HSV-1 and HSV-2 Virus Particles from Human Whole Blood by Binding to Heparin Immobilized on Sephadex Beads


The experimental procedure as described in Example 1 was utilized with the difference that the radiolabelled HSV-1 and HSV-2 virus particles at a quantity of equivalent to 1011 virus particles per ml were mixed with 1 ml of human blood and then applied to 1 ml heparin-coated beads in a disposable column. Thereafter, the procedure including elution and washing was followed as in Example 1.


The results are shown in Table 4 below. As shown, 99.1% of the HSV-1 particles and 99.8% of the HSV-2 particles suspended in human blood were bound to the column.









TABLE 4







Binding of radiolabelled HSV virus particles, suspended


in human blood, to heparin-Sephadex beads (1 cm3).


Binding of whole blood HSV to heparin column


(% of input virus = control = 100%)










HSV-1
HSV-2



%
%














Input virus (control)
100.0
100.0



Unadsorbed virus
0.9
0.2









Example 5

Removal of Influenza a Virus from Human Serum by Binding to Immobilized Oligosaccharides Containing Sialic Acid


Virus stocks of Influenza A H1N1 were replicated in MDCK cells grown at 35° C. under standard conditions for 3 days, after which the cells were homogenized and titrated to assess the number of focus-forming units (FFU)/ml. Virus particles were suspended in human serum to a final concentration of 106 FFU/ml. A 10 ml suspension was applied on a sialic acid-coated hollow fiber dialyzer, prepared using the method described in Preparatory example 7. After titrating the infectivity of the Influenza A-containing serum after passage through the dialyzer and comparing it with titers of an aliquot of the same virus-containing serum not passed through the device it was concluded that 87% of the Influenza A virus FFU remained bound to the fibers.


Example 6

Removal of Helicobacter pylori and Staphylococcus aureus by Binding to Immobilized Heparin


Four sterile pipettes were packed with glass wool (0.5 ml) that was heparinized as described in Preparatory example 3. The “columns” thus formed were washed with 3 ml of sterile phosphate saline buffer (PBS), pH 7.2. Two different strains of H. pylori and two different strains of S. aureus were tested. Each of the four different bacteria samples, suspended in PBS buffer, were applied to a separate “column”. The amounts of bacteria in the samples were measured before application to the column and after elution from the column by optical density (OD) at 560 nm and viable counts (CFU/ml). As is evident from the table below, roughly 90% of H. pylori and roughly 50% of S. aureus bacteria were immobilized on the columns.









TABLE 6







Binding of H. pylori and S. aureus to heparinized glass wool.











OD560
CFU/ml
Binding












Bacteria
In
Out
In
Out
%
















H. Pylori ATCC

8.33
0.81

2 × 108

1.5 × 107
~90


43504








H. Pylori ATCC

8.33
1.86

2 × 108


1 × 107

~90


43504








S. aureus CCUG

9.30
5.5
7.7 × 109
3.6 × 109
~50


12600








S. aureus CCUG

9.30
6.9
7.7 × 109
3.6 × 109
~50


12600








Claims
  • 1. A method for treating a subject in need thereof, by extracorporeal removal of a pathogenic microbe, said method comprising: a) contacting said subject's whole blood with heparin immobilized on a solid substrate, said heparin having a terminal residue, wherein heparin immobilization consists of a single covalent link of said terminal residue to said solid substrate by covalent end-point attachment, under conditions allowing binding of said pathogenic microbe in said subject's whole blood sample to the heparin;b) separating the whole blood from the solid substrate;c) recovering said whole blood containing a reduced amount of said pathogenic microbe; andd) reintroducing into said subject said whole blood containing a reduced amount of said pathogenic microbe.
  • 2. The method of claim 1, wherein said pathogenic microbe is a parasite.
  • 3. The method of claim 2, wherein said parasite is selected from the group consisting of Plasmodium falciparum and Trypanosoma cruzi.
  • 4. The method of claim 1, wherein said solid substrate comprises microparticles.
  • 5. The method of claim 1, wherein said solid substrate comprises fibers.
  • 6. The method of claim 1, wherein the material of said solid substrate is at least one member selected from the group consisting of glass, cellulose, cellulose acetate, chitin, chitosan, crosslinked dextran, crosslinked agarose, polypropylene, polyethylene, polysulfone, polyacrylonitrile, silicone, Teflon and polyurethanes.
Priority Claims (1)
Number Date Country Kind
05027503 Dec 2005 SE national
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation application of U.S. patent application Ser. No. 15/678,580, filed Aug. 16, 2017, allowed, which is a continuation application of U.S. patent application Ser. No. 14/873,133, filed Oct. 1, 2015, now U.S. Pat. No. 9,764,077, which is a continuation application of U.S. patent application Ser. No. 12/086,126, filed Sep. 10, 2008, now U.S. Pat. No. 9,173,989, which application is a 35 U.S.C. § 371 National Phase Application of PCT/SE2006/001421, filed Dec. 13, 2006, which application claims priority to SE 0502750-3, filed Dec. 13, 2005, the disclosures of which are hereby incorporated by reference in their entireties for all purposes.

US Referenced Citations (110)
Number Name Date Kind
3782382 Naftulin et al. Jan 1974 A
4103685 Lupien et al. Aug 1978 A
4415665 Mosbach et al. Nov 1983 A
4430496 Abbott Feb 1984 A
4613665 Larm Sep 1986 A
4637994 Tani et al. Jan 1987 A
4820302 Woodroof Apr 1989 A
4955870 Ridderheim et al. Sep 1990 A
5116962 Stueber et al. May 1992 A
5211850 Shettigar et al. May 1993 A
5403917 Boos et al. Apr 1995 A
5437861 Okarma et al. Aug 1995 A
5447859 Prussak Sep 1995 A
5476509 Keogh, Jr. et al. Dec 1995 A
5753227 Strahilevitz May 1998 A
6037458 Hirai et al. Mar 2000 A
6159377 Davankov et al. Dec 2000 A
6197568 Marks et al. Mar 2001 B1
6248127 Shah et al. Jun 2001 B1
6312907 Guo et al. Nov 2001 B1
6461665 Scholander Oct 2002 B1
6544727 Hei Apr 2003 B1
6559290 Nakatani et al. May 2003 B1
6653457 Larm et al. Nov 2003 B1
7179660 Kirakossian Feb 2007 B1
7408045 Maruyama et al. Aug 2008 B2
7695609 Soundarrajan et al. Apr 2010 B2
8663148 Larm et al. Mar 2014 B2
8758286 Ward et al. Jun 2014 B2
9173989 Larm et al. Nov 2015 B2
9408962 Ward et al. Aug 2016 B2
9669150 Larm et al. Jun 2017 B2
9764077 Larm et al. Sep 2017 B2
10086126 Ward et al. Oct 2018 B2
10188783 Larm et al. Jan 2019 B2
10457974 Ward et al. Oct 2019 B2
10487350 Ward et al. Nov 2019 B2
20010005487 Kamibayashi et al. Jun 2001 A1
20020018985 Eible et al. Feb 2002 A1
20020058032 Hirai et al. May 2002 A1
20020068183 Huang et al. Jun 2002 A1
20020197249 Brady et al. Dec 2002 A1
20020197252 Brady et al. Dec 2002 A1
20030021780 Smith et al. Jan 2003 A1
20030044769 Ogino et al. Mar 2003 A1
20030148017 Tuominen et al. Aug 2003 A1
20040084358 O'Mahony et al. May 2004 A1
20040115278 Putz et al. Jun 2004 A1
20040140265 Lihme Jul 2004 A1
20040176672 Silver et al. Sep 2004 A1
20040182783 Walker et al. Sep 2004 A1
20040185553 Hei Sep 2004 A9
20040202783 Baumann et al. Oct 2004 A1
20050098500 Collins et al. May 2005 A1
20050142542 Hei et al. Jun 2005 A1
20050244371 Lentz Nov 2005 A1
20050271653 Strahilevitz Dec 2005 A1
20060093999 Hei May 2006 A1
20060252054 Ping Nov 2006 A1
20070190050 Davidner et al. Aug 2007 A1
20070218514 Smith et al. Sep 2007 A1
20070231217 Clinton et al. Oct 2007 A1
20080021365 Kobayashi et al. Jan 2008 A1
20080138434 Brady et al. Jun 2008 A1
20080268464 Schumacher et al. Oct 2008 A1
20080314817 Fujita et al. Dec 2008 A1
20090105194 Flengsrud et al. Apr 2009 A1
20090136586 Larm et al. May 2009 A1
20090173685 Imai et al. Jul 2009 A1
20090206038 Thomas Aug 2009 A1
20090246800 Mattingly et al. Oct 2009 A1
20090325276 Battrell Dec 2009 A1
20100069816 Brady et al. Mar 2010 A1
20100079360 McLaughlin et al. Apr 2010 A1
20100098666 Wright Apr 2010 A1
20100112725 Babu et al. May 2010 A1
20100145317 Laster et al. Jun 2010 A1
20100216226 Hyde et al. Aug 2010 A1
20100217173 Hyde et al. Aug 2010 A1
20100239673 Linhardt Sep 2010 A1
20100249689 Larm et al. Sep 2010 A1
20100276359 Ippommatsu et al. Nov 2010 A1
20100291588 McDevitt Nov 2010 A1
20100326916 Wrazel et al. Dec 2010 A1
20110150911 Choo Jun 2011 A1
20110171713 Bluchel et al. Jul 2011 A1
20110184377 Ward et al. Jul 2011 A1
20110224645 Winqvist et al. Sep 2011 A1
20120040429 Federspiel et al. Feb 2012 A1
20120244557 Yu et al. Sep 2012 A1
20120305482 McCrea et al. Dec 2012 A1
20130102948 Reich et al. Apr 2013 A1
20130131423 Wang et al. May 2013 A1
20140012097 McCrea et al. Jan 2014 A1
20140131276 Larm et al. May 2014 A1
20140231357 Ward et al. Aug 2014 A1
20150111849 McCrea et al. Apr 2015 A1
20150260715 Hu et al. Sep 2015 A1
20160003858 McKendry et al. Jan 2016 A1
20160022898 Larm et al. Jan 2016 A1
20160082177 Ward et al. Mar 2016 A1
20160084835 Ward et al. Mar 2016 A1
20160101229 McCrea et al. Apr 2016 A1
20160214935 Hutchinson et al. Jul 2016 A1
20160331886 Ward et al. Nov 2016 A1
20170035956 McCrea et al. Feb 2017 A1
20170073727 Ward et al. Mar 2017 A1
20170340803 Larm et al. Nov 2017 A1
20180361050 Ward et al. Dec 2018 A1
20190038826 McCrea et al. Feb 2019 A1
Foreign Referenced Citations (81)
Number Date Country
101370536 Feb 2009 CN
102740859 Oct 2012 CN
4217917 Dec 1993 DE
0306617 Mar 1989 EP
0321703 Jun 1989 EP
0533946 Mar 1993 EP
0616845 Sep 1994 EP
0810027 Dec 1997 EP
1044696 Oct 2000 EP
1057529 Dec 2000 EP
1110602 Jun 2001 EP
1219639 Jul 2002 EP
2087916 Aug 2009 EP
2556849 Feb 2013 EP
2172812 Oct 1986 GB
54-127493 Sep 1979 JP
58-053757 Mar 1983 JP
58-146354 Aug 1983 JP
4-89500 Mar 1992 JP
6040926 Feb 1994 JP
6-505248 Jun 1994 JP
7-178161 Jul 1995 JP
96-510166 Oct 1996 JP
11-502703 Mar 1999 JP
2000-086688 Mar 2000 JP
2000-217575 Aug 2000 JP
2000-515543 Nov 2000 JP
2001-190273 Jul 2001 JP
2002-505101 Feb 2002 JP
2002-509518 Mar 2002 JP
2003-128502 May 2003 JP
2003-520048 Jul 2003 JP
2005-514127 May 2005 JP
2005-519744 Jul 2005 JP
2005-532130 Oct 2005 JP
2009-521413 Jun 2009 JP
2010-518046 May 2010 JP
2010-530288 Sep 2010 JP
2012-501708 Jan 2012 JP
2013-512078 Apr 2013 JP
2014-500735 Jan 2014 JP
10-2008-0077405 Aug 2008 KR
9104086 Apr 1991 WO
9214361 Sep 1992 WO
9426399 Nov 1994 WO
9505400 Feb 1995 WO
9629083 Sep 1996 WO
9640857 Dec 1996 WO
9735660 Oct 1997 WO
9805341 Feb 1998 WO
9829727 Jul 1998 WO
9906086 Feb 1999 WO
9945104 Nov 1999 WO
0023792 Apr 2000 WO
00038763 Jul 2000 WO
0066260 Nov 2000 WO
0118060 Mar 2001 WO
0153525 Jul 2001 WO
02060512 Aug 2002 WO
03033143 Apr 2003 WO
2003057356 Jul 2003 WO
2003078023 Sep 2003 WO
2004008138 Jan 2004 WO
2004009798 Jan 2004 WO
2005021799 Mar 2005 WO
2007058592 May 2007 WO
2007069983 Jun 2007 WO
2007101064 Sep 2007 WO
2007146162 Dec 2007 WO
2008095905 Aug 2008 WO
2008157570 Dec 2008 WO
2010029317 Mar 2010 WO
2011068897 Jun 2011 WO
2011100354 Aug 2011 WO
2012051595 Apr 2012 WO
2012112724 Aug 2012 WO
2012172341 Dec 2012 WO
2013188073 Dec 2013 WO
2014209782 Dec 2014 WO
2015069942 May 2015 WO
2015164198 Oct 2015 WO
Non-Patent Literature Citations (81)
Entry
GE Healthcare, “Size exclusion chromatography columns and resins, Selection guide,” 2010, retreived online at <<https://cdn.gelifesciences.com/dmm3bwsv3/AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=13947>> on Jun. 27, 2019, 10 pages.
Brat, D. et al., “The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis,” Neuro-oncology, 7(2):122-133, 2005.
Abdul-Razzak, K. et al., “Fetal and newborn calf thymus as a source of chromatin proteins: Purification of HMG-1 and HMG-2,” Preparative Biochemistry and Biotechnology, 17(1):51-61, 1987.
Alarabi, A. et al., “Treatment of pruritus in cholestatic jaundice by bilirubin- and bile acid-adsorbing resin column plasma perfusion,” Scandinavian Journal of Gastroenterology, 27(3):223-6, 1992.
Alfaro et al., “Interleukin-8 in cancer pathogenesis, treatment and follow-up,” Cancer Treat Rev., Nov. 2017, vol. 60:24-31 (abstract only).
Axelsson, J. et al., “Cytokines in blood from septic patients interact with surface-immobilized heparin,” ASAIO Journal, 56:48-51, 2010.
Bhakdi, S. and Tranum-Jensen, J., “Alpha-toxin of Staphylococcus aureus,” Microbiological Reviews, 55(4):733-751, 1991.
Bindslev et al., “Treatment of acute respiratory failure by extracorporeal carbon dioxide elimination performed with a surface heparinized artificial lung,” Anesthesiology, 67(1):117-120, 1987.
Bjorklund et al., Abstract of “Synthesis of silica-based heparin-affinity adsorbents,” J. Chrom. A., 728(1-2):149-169, 1996.
Celik, T. et al., “Treatment of lyme neuroborreliosis with plasmapheresis,” J. Clinical Apheresis, 31:476-478, 2016.
Chase, H., “Affinity separations utilising immobilised monoclonal antibodies—a new tool for the biochemical engineer,” Chemical Engineering Science, 39(7-8):1099-1125, 1984.
Chen et al., “Microbial subversion of heparin sulfate proteoglycans,” Mol. Cells, 26:415-426, 2008.
Dixon et al., “Anthrax,” New England Journal of Medicine, 341(11):815-826, 1999.
Dubreuil et al., “Effect of heparin binding on Helicobacter pylori resistance to serum,” J. Med. Micro., 53:9-12, 2004.
English translation of Chinese Office Action dated Mar. 23, 2011 for Application No. 200680052757.9.
English translation of Decision of Refusal dated Mar. 19, 2013 in Japanese Application No. 2008-545539.
English translation of Office Action dated Jul. 10, 2012 in Japanese Patent Application No. 2008-545539.
English translation of Russian Office Action dated Sep. 1, 2010 for Application No. 2008128416.
Examination report dated Apr. 14, 2010 in New Zealand Application No. 568754.
Examination report dated Jul. 20, 2011 in New Zealand Application No. 568754. [our 110NZ].
Francy, D. et al., “Comparison of filters for concentrating microbial indicators and pathogens in lake water samples,” Applied and Environmental Microbiology, 79(4):1342-52, 2012.
Fujita, M. et al., “Adsorption of inflammatory cytokines using a heparin-coated extracorporeal circuit,” Artificial Organs, 26(12):1020-1025, 2002.
Garg, L. et al., “Isolation and separation of HMG proteins and histones H1 and H5 and core histones by column chromatography on phosphocellulose,” Protein Expression and Purification, 14(2):155-159, 1998.
Haase et al., “The effect of three different miniaturized blood purification devices on plasma cytokine concentration in an ex vivo model of endotoxinemia,” Int. J. Artif. Organs, 31(8):722-729, 2008.
Hirmo, S. et al., “Sialyglycoconjugate- and proteoglycan-binding microbial lectins,” Institute of Medical Microbiology, University of Lund, (Online). Retrieved Oct. 19, 1997 (Retrieved on Mar. 16, 2004). Retrieved from the Internet: <URL: http//www.plab.ku.dk/tcbh/Lectins12/Hirmo/paper.htm>.
International Preliminary Report on Patentability, dated Aug. 21, 2013, PCT Application No. PCT/US2012/025316; 8 pages.
International Search Report; PCT/SE2006/001421 dated Mar. 30, 2007.
International Search Report; PCT/US2010/058596 dated Mar. 29, 2011.
International Search Report; PCT/US2011/024229 dated May 30, 2011.
International Search Report; PCT/US2012/025316 dated May 23, 2012.
International Search Report; PCT/US2013/042377 dated Sep. 9, 2013.
International Search Report; PCT/US2014/043358 dated Dec. 1, 2014.
International Search Report; PCT/US2014/064419 dated Feb. 12, 2015.
International Search Report; PCT/US2015/026340 dated Jul. 28, 2015.
International Search Report; PCT/US2015/051239 dated Dec. 17, 2015.
International Search Report; PCT/US2016/057121 dated Dec. 30, 2016.
International Search Report; PCT/US2017/058536; dated Jan. 17, 2018.
JP Interrogation for Appl. No. 2008-545539 dated Mar. 18, 2014.
Kenig, M. et al., “Identification of the heparin-binding domain of TNF-alpha and its use for efficient TNF-alpha purification by heparin-Sepharose affinity chromatography,” J. Chromatography B, 867:119-125, 2008.
Keuren et al., “Thrombogenecity of polysaccharide-coated surfaces,” Biomaterials, 24:1917-24, 2003.
Kim et al., “Role of the heparin in regulating a transcapillary exchange in far north conditions,” Bulletin of the Siberian Branch of the Russian Academy of Medical Sciences, 2(108), 2003.
Kishimoto, S. et al., “Human stem cell factor (SCF) is a heparin-binding cytokine,” J. Biochem., 145(3):275-278, 2009.
Kumari, N. et al., “Role of interleukin-6 in cancer progression and therapeutic resistance,” Tumour Biol., Sep. 2016, vol. 37(9), pp. 11553-11572 (abstract only).
Larm et al., “A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue,” Biomater Med Devices Artif Organs, 11(2&3):161-173, 1983.
Lian, S. et al., “Elevated expression of growth-regulated oncogene-alpha in tumor and stromal cells predicts unfavorable prognosis in pancreatic cancer,” Medicine, Jul. 2016, 95(30), pp. 1-8.
Lopatkin et al., “Efferent methods in medicine, M.,” Medicine, pp. 266, 272-273, 276-279, 1989.
Low, R. et al., “Protein n, a primosomal DNA replication protein of Escherichia coli,” Journal of Biological Chemistry, 257(11):6242-6250, 1982.
Mandal, “Sialic acid binding lectins,” Experientia, 46:433-439, 1990.
Mariano et al, “Tailoring high-cut-off membranes and feasible application in sepsis-associated acute renal failure: in vitro studies,” Nephrol Dial Transplant, 20:1116-1126, 2005.
Mattsby-Baltzer, I. et al., “Affinity apheresis for treatment of bacteremia caused by Staphylococcus aureus and/or methicillin-resistant S. aureus (MRSA),” J. Microbiol. Biotechnol., 21(6):659-664, 2011.
Millen, H. et al., “Glass wool filters for concentrating waterborne viruses and agricultural zoonotic pathogens,” J. Vis. Exp., 61:e3930, 2012.
Nadkarni et al., Abstract of “Directional immobilization of heparin onto beaded supports,” Anal. Biochem., 222(1):59-67, 1994.
Ofek et al., “Mannose binding and epithelial cell adherence of Escherichia coli,” Infection and Immunity, 22(1):247-254, 1978.
Park, P. et al., “Activation of Syndecan-1 ectodomain shedding by Staphylococcus aureus α-toxin and β-toxin,” J. Biol. Chem., 279(1):251-258, 2004.
Popova et al., “Acceleration of epithelial cell syndecan-1 shedding by anthrax hemolytic virulence factors,” BMC Microbiolgy, 6:8, pp. 1-16, 2006.
Rauvala, H. et al., “Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons,” Journal of Biological Chemistry, 262(34):16625-16635, 1987.
Rauvala, H. et al., “The adhesive and neurite-promoting molecule p30: Analysis of the amino-terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons,” Journal of Cell Biology, 107(6,1):2293-2305, 1988.
Riesenfeld et al., “Quantitative analysis of N-sulfated, N-acetylated, and unsubstituted glucosamine amino groups in heparin and related polysaccharides,” Anal Biochem, 188:383-389, 1990.
Sagnella et al., “Chitosan based surfactant polymers designed to improve blood compatibility on biomaterials,” Colloids and Surfaces B: Biointerfaces, 42:147-155, 2005.
Salek-Ardakani, S. et al., “Heparin and heparan sulfate bind interleukin-10 and modulate its activity,” Blood, 96:1879-1888, 2000.
Salmivirta, M. et al., “Neurite growth-promoting protein (Amphoterin, p30) binds syndecan,” Experimental Cell Research, 200:444-451, 1992.
Sanchez, J. et al., “Control of contact activation on end-point immobilized heparin: The role of antithrombin and the specific antithrombin-binding sequence,” J. Bio. Mat. Res., 29:665-661, 1995.
Sasaki et al., Abstract: “Improved method for the immobilization of heparin,” J. Chrom., 400:123-32, 1987.
Sato, T. et al., “Experimental study of extracorporeal perfusion for septic shock,” Asaio Journal, 39(3):M790-M793, 1993.
Schefold et al., “A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5A,” Shock, 28(4):418-425, 2007.
Sharon, “Bacterial lectins, cell-cell recognition and infectious disease,” FEBS letters, 217(2):145-157, 1987.
Supplementary European Search Report issued in European Application No. EP06835845 dated Mar. 26, 2013.
Swartz, “Recognition and management of anthrax—an update,” New Engl. J. Med., 345(22):1621-1626, 2001.
Thomas et al., “Common oligosaccharide moieties inhibit the adherence of typical and atypical respiratory pathogens,” Journal of Microbiology, 53:833-840, 2004.
Utt, M. et al., “Identification of heparan sulphate binding surface proteins of Helicobacter pylori: inhibition of heparan sulphate binding with sulphated carbohydrate polymers,” J. Med. Microbiol., 46:541-546, 1997.
Wang, H. et al., “HMG-1 as a late mediator of endotoxin lethality in mice,” Science, 285:248-251, 1999.
Ward et al., “Specificity of adsorption in a prototype whole blood affinity therapy device for removal of Staphylococcus aureus,” Society for Biomaterials 2013 Annual Meeting and Exposition, Apr. 10, 2013, p. 1.
Waugh D. and Wilson, C., “The interleukin-8 pathway in cancer,” Clin. Cancer Res., 14(21):6735-41, 2008.
Webb, L. et al., “Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8,” PNAS USA, 90:7158-62, 1993.
Weber et al., “Development of specific adsorbents for human tumor necrosis factor-α: influence of antibody immobilization on performance and biocompatibility,” Biomacromolecules, 6:1864-1870, 2005.
Weir, D., “Carbohydrates as recognition molecules in infection and immunity,” FEMS Microbiology Immunology, 47:331-340, 1989.
Wendel et al., “Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation,” European Journal of Cardio-thoracic Surgery, 16:342-350, 1999.
Yu, J. et al., “Adhesion of coagulase-negative staphylococci and adsorption of plasma proteins to heparinized polymer surfaces,” Biomaterials, 15(10):805-814, 1994.
Zhou et al., Abstract: “Heparin-agarose aqueous ethanol suspension,” J. Mol. Bio., 271(3):12, 1997.
Ghannoum, M. et al., “Extracorporeal treatment for carbamazepine poisoning: Systematic review and recommendations from the EXTRIP workgroup,” Clinical Toxicology, 52:993-1004, 2014.
Lemaire, M. et al., “Treatment of paediatric vancomycin intoxication: a case report and review of the literature,” NDT Plus, 3:260-264, 2010.
Related Publications (1)
Number Date Country
20190143027 A1 May 2019 US
Continuations (3)
Number Date Country
Parent 15678580 Aug 2017 US
Child 16247372 US
Parent 14873133 Oct 2015 US
Child 15678580 US
Parent 12086126 US
Child 14873133 US